Cargando…

Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan

BACKGROUND: The WHO recommends the use of bedaquiline (BDQ) in longer, as well as shorter, multi-drug-resistant TB (MDR-TB) treatment regimens. However, resistance to this new drug is now emerging. We aimed to describe the characteristics of patients in Karakalpakstan, Uzbekistan, who were treated f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nair, P., Hasan, T., Zaw, K. K., Allamuratova, S., Ismailov, A., Mendonca, P., Bekbaev, Z., Parpieva, N., Singh, J., Sitali, N., Bermudez-Aza, E., Sinha, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Union Against Tuberculosis and Lung Disease 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272738/ https://www.ncbi.nlm.nih.gov/pubmed/35768925 http://dx.doi.org/10.5588/ijtld.21.0631

Ejemplares similares

Primary bedaquiline resistance in Karakalpakstan, Uzbekistan
por: Moe, S., et al.
Publicado: (2023)

Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan
por: Trauer, James M., et al.
Publicado: (2016)

Multidrug-Resistant Tuberculosis Treatment Outcomes in Karakalpakstan, Uzbekistan: Treatment Complexity and XDR-TB among Treatment Failures
por: Cox, Helen S., et al.
Publicado: (2007)

Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan
por: du Cros, Philipp, et al.
Publicado: (2021)

Programme costs of longer and shorter tuberculosis drug regimens and drug import: a modelling study for Karakalpakstan, Uzbekistan
por: Kohler, Stefan, et al.
Publicado: (2022)

Patient and health-care worker perspectives on the short-course regimen for treatment of drug-resistant tuberculosis in Karakalpakstan, Uzbekistan
por: Horter, Shona, et al.
Publicado: (2020)

Where there is hope: a qualitative study examining patients’ adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan
por: Horter, Shona, et al.
Publicado: (2016)

The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan
por: Kohler, Stefan, et al.
Publicado: (2022)

Person-centred care in practice: perspectives from a short course regimen for multi-drug resistant tuberculosis in Karakalpakstan, Uzbekistan
por: Horter, Shona, et al.
Publicado: (2020)

2389. Surveillance evaluation of COVID-19 pharmacovigilance—Karakalpakstan, Uzbekistan, 2022
por: Tursinov, Yunis, et al.
Publicado: (2023)

Assessment of dietary exposure to some persistent organic pollutants in the Republic of Karakalpakstan of Uzbekistan.
por: Muntean, Nigina, et al.
Publicado: (2003)

Genetic Polymorphism of 27 Y-STR Loci in the Western Kazakh Tribes from Kazakhstan and Karakalpakstan, Uzbekistan
por: Ashirbekov, Yeldar, et al.
Publicado: (2022)

MON-322 The Characteristic of Reproductive Disorders in Women with ACTH-Dependent Cushing Syndrome in the Republic of Uzbekistan (RUz) and Republic of Karakalpakstan (RKK)
por: Khalimova, Zamira Yusufovna, et al.
Publicado: (2020)

Efficacy of Pharmacopuncture for Treating Children with Physical Disabilities in Uzbekistan
por: Ismailov N, Zohidjon, et al.
Publicado: (2013)

Factors Associated with Unfavourable Treatment Outcomes in Patients with Tuberculosis: A 16-Year Cohort Study (2005–2020), Republic of Karakalpakstan, Uzbekistan
por: Gadoev, Jamshid, et al.
Publicado: (2021)

Epidemiology of hip fracture and the development of a FRAX model for Uzbekistan
por: Lesnyak, O, et al.
Publicado: (2020)

Characteristics and Treatment Outcomes of Patients with Tuberculosis Receiving Adjunctive Surgery in Uzbekistan
por: Riskiyev, Anvar, et al.
Publicado: (2021)

Hospitalizations and Treatment Outcomes in Patients with Urogenital Tuberculosis in Tashkent, Uzbekistan, 2016–2018
por: Ismatov, Bakhtiyor, et al.
Publicado: (2021)

Adverse Drug Reactions among Children with Tuberculosis in Tashkent, Uzbekistan, 2019
por: Abdusalomova, Makhliyo, et al.
Publicado: (2021)

Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
por: Andries, Koen, et al.
Publicado: (2014)

Assessing the Effectiveness of Type 2 Diabetes Screening in the Republic of Uzbekistan
por: Alieva, Anna, et al.
Publicado: (2022)

Operational Research to Inform Programmatic Approaches to the Management of Tuberculosis in Uzbekistan
por: Gadoev, Jamshid, et al.
Publicado: (2021)

Risk Factors Associated with Default from Multi- and Extensively Drug-Resistant Tuberculosis Treatment, Uzbekistan: A Retrospective Cohort Analysis
por: Lalor, Maeve K., et al.
Publicado: (2013)

Household Coverage with Adequately Iodized Salt and Iodine Status of Nonpregnant and Pregnant Women in Uzbekistan
por: Rohner, Fabian, et al.
Publicado: (2020)

Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy?
por: Usmanova, Ruzilya, et al.
Publicado: (2021)

Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018
por: Sayfutdinov, Zayniddin, et al.
Publicado: (2021)

Universal Access to Xpert MTB/RIF Testing for Diagnosis of Tuberculosis in Uzbekistan: How Well Are We Doing?
por: Turaev, Laziz, et al.
Publicado: (2021)

Trends, Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013–2018
por: Safaev, Khasan, et al.
Publicado: (2021)

Assessment of the Impact of the Rotavirus Vaccine Against Severe Rotaviral Diarrhea in Uzbekistan
por: Musabaev, Erkin, et al.
Publicado: (2023)

Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
por: Achar, Jay, et al.
Publicado: (2017)

Diagnostic Procedures, Diagnoses, and Treatment Outcomes of Patients with Presumptive Tuberculosis Pleural Effusion in Uzbekistan
por: Abdugapparov, Fazlkhan, et al.
Publicado: (2021)

Recurrent tuberculosis and associated factors: A five - year countrywide study in Uzbekistan
por: Gadoev, Jamshid, et al.
Publicado: (2017)

Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review
por: Mallick, Jahan Saeed, et al.
Publicado: (2022)

Mental health in Uzbekistan
por: Gazizova, Dina, et al.
Publicado: (2011)

Scaling Up Molecular Diagnostic Tests for Drug-Resistant Tuberculosis in Uzbekistan from 2012–2019: Are We on the Right Track?
por: Yuldashev, Sharofiddin, et al.
Publicado: (2021)

Risk Factors for Unfavorable Treatment Outcomes among the Human Immunodeficiency Virus-Associated Tuberculosis Population in Tashkent City, Uzbekistan: 2013–2017
por: Massavirov, Sherali, et al.
Publicado: (2021)

Maleate salts of bedaquiline
por: Zeller, Matthias, et al.
Publicado: (2021)

Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
por: Millard, James, et al.
Publicado: (2023)

Incidence Rate and Risk Factors for Tuberculosis among People Living with HIV: A 2015–2017 Cohort from Tashkent, Uzbekistan
por: Sadirova, Dilbar, et al.
Publicado: (2021)

Salts and Polymorph Screens for Bedaquiline
por: Okezue, Mercy, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ilkeohgrf8r5lcdsmf132g25nk